Explore more Articles in

BioTech

Oil: Can the Market Absorb OPEC+ Output Hikes?

OPEC+ surprised markets by announcing a larger-than-expected August output hike of 548,000 bpd. Analysts say actual supply increases remain limited due to ongoing compensation cuts. Strong...

US Dollar Fights an Uphill Battle Amidst Mounting Tariff Pressure

More Trump letters to be sent, with copper, chips, and pharma next on the tariff list Dollar struggles to hold recent gains, except versus the...

Big Oil Faces Weaker Quarter, but OPEC+ Output Move Signals Underlying Strength

Shell and Exxon warned of weaker Q2 earnings due to lower oil and gas prices, with Exxon expecting a $1.5 billion hit. Despite bearish forecasts,...

Gold Prices Fall on Fed Caution and Tariff Escalation

Fed’s Caution Tempers Gold Investors’ Enthusiasm Gold () declined by over 1% on Tuesday as a restrained dovish tone from the (Fed) tempered investor...

Amgen’s Gastric Cancer Drug Improves Survival In Phase 3, Notes Ocular Side Effects – Amgen (NASDAQ:AMGN)

Amgen Inc AMGN on Monday released data from the Phase 3 FORTITUDE-101 trial of first-line bemarituzumab plus chemotherapy (mFOLFOX6).The study met its primary endpoint...

Aardvark’s Hunger-Suppressing Drug Promises Weight Loss Without GI Distress – Aardvark Therapeutics (NASDAQ:AARD)

HC Wainwright initiated coverage on Aardvark Therapeutics, Inc. AARD on Monday with a Buy rating and a price forecast of $40.In February, Aardvark Therapeutics,...

Vor Biopharma’s $125 Million Investment Paves Way For Multi-Billion Dollar Autoimmune Market – Vor Biopharma (NASDAQ:VOR)

H.C. Wainwright upgraded Vor Biopharma Inc. VOR, highlighting the company’s “rebirth” following the in-licensing of telitacicept.On Thursday, the company announced a strategic licensing agreement...

FDA Flags Major Safety Concerns For Argenx’s Nerve Disorder Drug, Stock Falls – argenx (NASDAQ:ARGX)

Argenx SE ARGX stock is trading lower on Monday after the U.S. Food and Drug Administration (FDA) signaled serious risks/safety identified by the reporting...

Alzheimer’s Setback Hits INmune Bio Stock, But FDA Hopes Remain – INmune Bio (NASDAQ:INMB)

INmune Bio Inc. INMB stock is trading lower on Monday, with a session volume of 23.2 million, compared to the average volume of 1.45...

Why Is Micro-Cap Artelo Biosciences Stock Trading Higher On Monday? – Artelo Biosciences (NASDAQ:ARTL)

Artelo Biosciences, Inc. ARTL stock is trading higher on Monday, with a session volume of 11.7 million, compared to the average volume of 70.3K, as...

- A word from our sponsors -

Most Popular